Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Cancer ; 109(4): 658-67, 2007 Feb 15.
Article in English | MEDLINE | ID: mdl-17211865

ABSTRACT

BACKGROUND: The prognosis for patients with esophageal and esophagogastric junction (EGJ) adenocarcinoma remains poor, even after surgical resection. Pathologic assessment of depth of invasion and lymph node status are the primary prognostic factors in these patients. In patients with esophageal squamous cell carcinoma, increased epidermal growth factor receptor (EGFR) expression has been associated with a worse prognosis. It is not known whether EGFR plays a similar role in esophageal and EGJ adenocarcinomas. METHODS: To address this issue, the authors studied tumor specimens from 103 patients with surgically resected esophageal and EGJ adenocarcinomas (9 patients with stage I disease, 23 patients with stage II disease, 57 patients with stage III disease, and 14 patients with stage IV disease). The expression of EGFR was assessed by immunohistochemical analysis of tissue microarrays. Tumors were considered positive for EGFR expression when >5% of tumor cells were stained and negative when

Subject(s)
Adenocarcinoma/metabolism , Carcinoma, Squamous Cell/metabolism , ErbB Receptors/metabolism , Esophageal Neoplasms/metabolism , Esophagogastric Junction/metabolism , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/pathology , Disease-Free Survival , Esophageal Neoplasms/pathology , Esophagogastric Junction/pathology , Female , Gene Expression Regulation, Neoplastic , Humans , Immunoenzyme Techniques , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Prognosis , Survival Rate , Tissue Array Analysis
2.
Hum Pathol ; 38(2): 239-46, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17056094

ABSTRACT

The precursor lesions of renal cell carcinoma (RCC) are unknown. The purpose of this study is to determine the incidence, histomorphological features, and immunohistochemical features of papillary adenoma and elucidate its potential relationship to RCC. We reviewed 542 consecutive nephrectomy specimens over an 8-year period. Immunohistochemistry was carried out with antibodies specific for alpha-methyl-coenzyme A racemase (AMACR) and glutathione S-transferase alpha (clear-cell RCC marker). Thirty-eight (7%) nephrectomy specimens showed histologic evidence of papillary adenoma. Of these 38 cases, 18 (47%) arose in the setting of papillary RCC (PRCC). Seven papillary adenomas (18%) occurred in the setting of acquired polycystic kidney disease (APKD), 6 in clear-cell RCCs, 3 in chromophobe RCCs, 2 in end-stage kidney disease, 1 in oncocytoma, 1 in angiomyolipoma, and 1 in renal schwannoma. Furthermore, papillary adenomas were more commonly found in kidneys removed for PRCC (25%, 18/71) than in kidneys harboring clear-cell RCC (1.9%, 6/318). Histomorphologically, papillary adenomas were characterized by varying proportions of papillae and tubules formed by cuboidal cells with scant basophilic cytoplasm similar to those in type 1 PRCC. Adenomas associated with PRCC tend to be multiple in number (61% [11/18] of cases had >2 adenomas; mean, 5). In contrast, 100% of papillary adenomas arising in other conditions had less than 2 adenomas. Most of the adenomas (82%, 31/38) stained strongly for AMACR in a fashion similar to that of PRCC. The 7 AMACR-negative cases all arose in the setting of APKD. In this study of surgical specimens, the high coincidence, multifocality, and histologic and immunohistochemical similarities between papillary adenoma and PRCC suggest that the 2 are strongly associated and may represent a continuum of 1 biologic process. In contrast, adenomas associated with APKD exhibit distinct morphological and immunohistochemical features and, therefore, may have an entirely different pathogenesis.


Subject(s)
Carcinoma, Papillary/pathology , Carcinoma, Renal Cell/pathology , Kidney Neoplasms/pathology , Adenocarcinoma, Clear Cell/enzymology , Adenocarcinoma, Clear Cell/pathology , Adenoma , Adenoma, Oxyphilic/enzymology , Adenoma, Oxyphilic/pathology , Adult , Aged , Aged, 80 and over , Angiomyolipoma/enzymology , Angiomyolipoma/pathology , Carcinoma, Papillary/enzymology , Carcinoma, Renal Cell/enzymology , Disease Progression , Female , Glutathione Transferase/analysis , Humans , Immunohistochemistry , Isoenzymes/analysis , Kidney/enzymology , Kidney/pathology , Kidney Failure, Chronic/enzymology , Kidney Failure, Chronic/pathology , Kidney Neoplasms/enzymology , Male , Middle Aged , Models, Biological , Polycystic Kidney Diseases/enzymology , Polycystic Kidney Diseases/pathology , Racemases and Epimerases/analysis
3.
Cancer ; 107(7): 1467-74, 2006 Oct 01.
Article in English | MEDLINE | ID: mdl-16955509

ABSTRACT

BACKGROUND: Esophageal and esophagogastric junction (EGJ) adenocarcinomas frequently have neuroendocrine (NE) differentiation, but the significance of NE differentiation in patients who have undergone preoperative chemoradiation and resection remains unclear. METHODS: The authors evaluated the presence of NE differentiation in esophageal and EGJ adenocarcinomas by immunohistochemistry for chromogranin A and synaptophysin and evaluated the clinical significance of NE differentiation in 83 patients (10 patients who had a complete tumor response and 73 patients who had residual tumor in resection specimens) who received preoperative chemoradiation. RESULTS: Of 73 patients who had residual tumor after preoperative treatment, 52% showed NE differentiation. The proportion of tumor cells with NE differentiation had increased from 6% +/- 18% in pretreatment biopsy specimens to 47% +/- 42% (P = .00003) in posttreatment resection specimens in 30 patients who had paired pretreatment biopsy and resection specimens available. Disease-free survival (P = .002) and overall survival (P = .006) were significantly better in patients who had a complete tumor response than in patients who had residual tumor. Among patients who had residual tumor after preoperative chemoradiation, disease-free survival (P = .03) and overall survival (P = .045) were significantly better in patients who had residual tumor without NE differentiation than in patients who had residual tumor with NE differentiation. In multivariate analysis, the presence of NE differentiation in residual tumor was a prognostic factor for worse disease-free survival (P = .02) independent of pathologic stage and extent of residual tumor. CONCLUSIONS: The results from this study suggested that tumor cells with NE differentiation were more resistant to neoadjuvant chemoradiation in patients with esophageal and EGJ adenocarcinomas. The presence of NE differentiation in residual tumor was associated with poor survival after preoperative neoadjuvant therapy.


Subject(s)
Adenocarcinoma/pathology , Esophageal Neoplasms/pathology , Esophagogastric Junction/pathology , Neoadjuvant Therapy , Neuroendocrine Tumors/pathology , Adenocarcinoma/therapy , Aged , Cell Differentiation , Chromogranin A , Chromogranins/analysis , Disease-Free Survival , Esophageal Neoplasms/therapy , Female , Humans , Male , Middle Aged , Neoplasm, Residual , Preoperative Care , Prognosis , Synaptophysin/analysis
4.
Clin Cancer Res ; 12(15): 4598-604, 2006 Aug 01.
Article in English | MEDLINE | ID: mdl-16899607

ABSTRACT

PURPOSE: Annexin A1 (ANXA1) is a calcium-binding protein involved in arachidonic acid metabolism and epidermal growth factor receptor tyrosine kinase pathway. ANXA1 has been implicated in early squamous cell carcinogenesis of esophagus and correlates with degree of tumor differentiation. However, the role of ANXA1 in esophageal adenocarcinoma is unclear. Our goal was to evaluate ANXA1 expression and determine its prognostic significance in adenocarcinoma of the esophagus and esophagogastric junction. EXPERIMENTAL DESIGN: This study included 104 consecutive patients with primary resected esophageal and esophagogastric junction adenocarcinomas (11 stage I, 24 stage II, 53 stage III, and 16 stage IV). ANXA1 protein expression in each tumor was assessed by immunohistochemical staining of tissue microarrays. ANAX1 expression level was classified as high (>/=25% of tumor cells with cytoplasmic staining), low (<25% of tumor cells with cytoplasmic staining), or negative; and was correlated with clinicopathologic features and patients' outcomes. RESULTS: High ANXA1 expression was present in 39% (41 of 104) of tumors and was associated with higher pathologic T stage (P = 0.03) and distant metastasis (P = 0.04). High ANXA1 expression correlated with increased recurrence rate (P = 0.004) and decreased overall survival (P = 0.003) in univariate analysis. In multivariate analysis, ANXA1 expression and pN stage significantly correlated with recurrence rate (P = 0.008 and P < 0.001, respectively) and overall survival (P = 0.02 and P < 0.001, respectively) independent of T stage. CONCLUSION: Our results indicate that high ANXA1 expression is frequent in esophageal and esophagogastric junction adenocarcinomas, correlates with more advanced pathologic T stage and the presence of distant metastasis, and is an independent prognostic factor for patient survival.


Subject(s)
Adenocarcinoma/metabolism , Annexin A1/biosynthesis , Esophageal Neoplasms/metabolism , Esophagogastric Junction/metabolism , Esophagogastric Junction/pathology , Adenocarcinoma/diagnosis , Adenocarcinoma/therapy , Adult , Aged , Aged, 80 and over , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/therapy , Esophagogastric Junction/surgery , Female , Follow-Up Studies , Humans , Immunohistochemistry , Male , Middle Aged , Multivariate Analysis , Neoplasm Staging , Prognosis , Survival Analysis , Tissue Array Analysis , Treatment Outcome
6.
Hum Pathol ; 35(10): 1288-91, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15492999

ABSTRACT

Gangliocytic paraganglioma (GP) is a rare, typically benign tumor that shows neuroectodermal (neurosustentacular or Schwannian and neuronal) and neuroendocrine differentiation. Once thought to arise exclusively in the periampullary region as a solitary lesion, recent reports have documented both origin of GP in a variety of extra-duodenal sites as well as synchronous multifocal presentation of the tumor. Herein, we describe the first reported case of simultaneous occurrence of GP in the superior mediastinum and esophagus. A mass in the mid-distal esophagus and a separate mass in the superior mediastinum at the thoracic inlet were found in a 58-year-old woman by computed tomography scan. Subsequent biopsy of the superior mediastinal mass showed nests of epithelioid tumor cells coexisting with ganglioneuromatous elements, whereas biopsy of the esophageal mass showed nests of epithelioid cells with interspersed ganglion cells. The epithelioid tumor cells showed diffuse immunohistochemical expression of keratin (CAM 5.2), chromogranin, and synaptophysin supporting true neuroendocrine differentiation; ganglion cells expressed S-100 protein and neurofilament protein; and the spindled elements expressed S-100 protein, neurofilament protein, and glial fibrillary acidic protein indicating Schwannian differentiation. The finding of another GP occurring outside the periampullary region bolsters the argument for a stem cell origin of this unusual tumor.


Subject(s)
Esophageal Neoplasms/diagnosis , Mediastinal Neoplasms/diagnosis , Paraganglioma/diagnosis , Esophageal Neoplasms/pathology , Female , Humans , Immunohistochemistry , Mediastinal Neoplasms/pathology , Middle Aged , Paraganglioma/pathology , Tomography, Emission-Computed
8.
Arch Pathol Lab Med ; 128(10): 1136-41, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15387709

ABSTRACT

CONTEXT: Common fibrous histiocytoma (cFH) or dermatofibroma and dermatofibrosarcoma protuberans (DFSP) are 2 spindle cell mesenchymal tumors that are distinguished in part by their microscopic growth patterns and clinically by the greater propensity for DFSP to recur. Matrix metalloproteinases (MMPs) potentially play a role in modulating the growth patterns of cFH and DFSP by remodeling the extracellular matrix. OBJECTIVE: To evaluate the immunohistochemical (IHC) expression of MMP-1, MMP-2, MMP-9, and MMP-14 in DFSP and cFH, because (1) MMP-1, MMP-2, MMP-9, and MMP-14 are synthesized by dermal fibroblasts, the major constituent of DFSP and cFH; and (2) platelet-derived growth factor B, which is overexpressed in most examples of DFSP because of t(17;22), activates ets-1, a transcription factor that regulates molecules associated with tumor invasion and metastasis, including MMP-1, MMP-3, and MMP-9. DESIGN: Immunohistochemical studies were performed on archived, formalin-fixed, paraffin-embedded tissue of DFSP (n = 48) and cFH (n = 47).Results.-Significant IHC expression (>10% of tumor cells) in cFH included MMP-14 (27 [59%] of 46 tumors positive), MMP-2 (21 [47%] of 45 tumors positive), MMP-9 (9 [20%] of 45 tumors positive), and MMP-1 (6 [13%] of 46 tumors positive). No DFSPs showed significant IHC expression of any of the MMPs evaluated. However, anti- MMP-2 highlighted a rich microvascular element within deep tumor tissue present in 81% of DFSPs with a prominent subcutaneous component. CONCLUSION: Our IHC results indicate that MMP-1 and MMP-9 are not up-regulated in DFSP. Convincing expression of MMP-14 in cFH suggests that this MMP may affect the growth pattern of the lesion, perhaps by activating MMP-2 expression in tumor cells. In DFSP, MMP-2 may play a role in tumor angiogenesis.


Subject(s)
Dermatofibrosarcoma/enzymology , Histiocytoma, Benign Fibrous/enzymology , Immunohistochemistry/methods , Matrix Metalloproteinases/biosynthesis , Skin Neoplasms/enzymology , Dermatofibrosarcoma/pathology , Formaldehyde/metabolism , Histiocytoma, Benign Fibrous/pathology , Humans , Matrix Metalloproteinase 1/biosynthesis , Matrix Metalloproteinase 1/immunology , Matrix Metalloproteinase 2/biosynthesis , Matrix Metalloproteinase 2/immunology , Matrix Metalloproteinase 9/biosynthesis , Matrix Metalloproteinase 9/immunology , Matrix Metalloproteinases/immunology , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/biosynthesis , Metalloendopeptidases/immunology , Paraffin Embedding/methods , Skin Neoplasms/pathology , Tissue Fixation/methods
10.
Oncol Rep ; 11(5): 951-6, 2004 May.
Article in English | MEDLINE | ID: mdl-15069531

ABSTRACT

Colon carcinoma arising in inflammatory bowel disease often exhibits aggressive behavior compared to sporadic carcinomas. The rationale for the different biological behaviors of these two groups of tumors is not fully understood. In this study, we have examined carcinomas arising in inflammatory bowel disease (IBD) and sporadic carcinomas (SCA) for molecular differences that may provide clues for the behavioral disparity of these tumors. Thirty-eight colon carcinomas (12 from ulcerative colitis, 5 from Crohn's disease, and 21 SCA) were analyzed by immunohistochemistry for cell adhesion molecules (E-cadherin, beta-catenin, CD44), cell cycle regulatory proteins (cyclin D1, p27, p21), mismatch repair proteins (hMLH1, hMSH2), cyclooxygenase-2 and DPC4. Carcinomas arising in IBD showed significant decrease in expression of cell adhesion molecules, the cell cycle inhibitor protein, p21, and increased expression of cyclooxygenase-2 compared to sporadic carcinomas. No differences were observed in the expression of cell cycle regulatory proteins p27, cyclin D1, DPC4 and mismatch repair proteins between these two groups of tumors. Decreased expression of p21 as well as adhesion molecules may provide increased impetus for the aggressive behavior of tumors arising in inflammatory bowel disease.


Subject(s)
Base Pair Mismatch/physiology , Cell Adhesion Molecules/metabolism , Cell Cycle Proteins/metabolism , Colonic Neoplasms/metabolism , DNA-Binding Proteins/metabolism , Inflammatory Bowel Diseases/metabolism , Isoenzymes/metabolism , Prostaglandin-Endoperoxide Synthases/metabolism , Trans-Activators/metabolism , Adaptor Proteins, Signal Transducing , Cadherins/metabolism , Carrier Proteins , Colonic Neoplasms/complications , Colonic Neoplasms/enzymology , Cyclin D1/metabolism , Cyclin-Dependent Kinase Inhibitor p21 , Cyclin-Dependent Kinase Inhibitor p27 , Cyclins/metabolism , Cyclooxygenase 2 , Cytoskeletal Proteins/metabolism , Gene Expression Profiling , Humans , Hyaluronan Receptors/metabolism , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/enzymology , Membrane Proteins , MutL Protein Homolog 1 , MutS Homolog 2 Protein , Neoplasm Proteins/metabolism , Nuclear Proteins , Proto-Oncogene Proteins/metabolism , Smad4 Protein , Tumor Suppressor Proteins/metabolism , beta Catenin
SELECTION OF CITATIONS
SEARCH DETAIL
...